Acetate
|
(11C)a
|
Acetate
|
22
|
Choline
|
(11C)a
|
2-Hydroxy-N,N,N-trimethylethan-1-aminium
|
16
|
Choline
|
(18F)a
|
2-Hydroxy-N,N,N-trimethylethan-1-aminium
|
37
|
Choline
|
NOSa
|
2-Hydroxy-N,N,N-trimethylethan-1-aminium
|
7
|
Citrate
|
(68Ga)
|
2-Hydroxypropane-1,2,3-tricarboxylic acid
|
1
|
DFO-huJ591
|
(89Zr)
|
Recombinant humanized monoclonal antibody J591 conjugated to chelator desferrioxamine B
|
1
|
DFO-MSTP2109A
|
(89Zr)
|
Desferrioxamine - DFO-MSTP2109A is an antibody that works against STEAP1 - found on the surface of prostate cancer cells
|
1
|
DHT
|
(18F)a
|
(5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
|
3
|
DOTA-Bombesin
|
(68Ga)
|
68Ga-DOTA-Bombesin is a gallium-68-labeled gastrin-releasing peptide receptor (GRPr) antagonist. DOTA is [4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]-acetyl.
|
1
|
DOTATET
|
(68Ga)
|
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (also known as DOTA)
|
1
|
FAZA
|
(18F)
|
Nitroimidazole nucleoside analogue 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole (FAZA)
|
2
|
FDG
|
(18F)a
|
2-Deoxy-2-[18F]fluoroglucose
|
15
|
FLT
|
(18F)
|
1-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
|
1
|
Fluciclovine
|
(18F)
|
Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid
|
13
|
Fluciclovine
|
(NOS)
|
Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid
|
1
|
Fluorocholine
|
(18F)
|
Fluoromethyl-(2-hydroxyethyl)-dimethylazanium;chloride
|
1
|
FMAU
|
(18F)
|
2′-deoxy-2′-[18F]fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (fluorine F 18 d-FMAU [18F-FMAU]),
|
3
|
MeAIB
|
(NOS)a
|
2-methyl-2-(methylamino)propanoic acid
|
1
|
Methionine
|
(11C)a
|
(2S)-2-amino-4-methylsulfanylbutanoic acid
|
3
|
MISO
|
(18F)
|
1-methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol
|
1
|
NaF
|
(18F)a
|
Sodium;fluoride
|
20
|
NODAGA-MJ9
|
(Ga-68)a
|
1,4,7-triazacyclononane,1-glutaric acid-4,7 acetic acid (NODAGA)
|
1
|
NOTA-BBN-RGD
|
(68Ga)
|
1,4,7-triazacyclononanetriacetic acid (NOTA), Arg-Gly-Asp (RGD) and bombesin (BBN)
|
1
|
P15–041
|
(68Ga)
|
Unknown
|
1
|
PACAP
|
(64Cu)
|
Pituitary adenylate cyclase-activating peptide
|
2
|
Peripheral Benzodiazepine Receptor-28
|
(11C)
|
Peripheral Benzodiazepine Receptor-28
|
1
|
PSMA DCFPyL
|
(18F)a
|
N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine ([18F]DCFBC)
|
21
|
PSMA
|
(68Ga)
|
Glutamate carboxypeptidase II, also known as N-acetyl-L-aspartyl-L-glutamate peptidase I
|
15
|
PSMA
|
(89Zr)
|
Glutamate carboxypeptidase II, also known as N-acetyl-L-aspartyl-L-glutamate peptidase I
|
2
|
PSMA CTT 1057
|
(NOS)
|
Cancer Targeted Technology (CTT), a privately held Seattle-based biotechnology firm that will develop the agent, CTT1057. CTT1057 is a small molecule that homes in and binds irreversibly to prostate specific membrane antigen (PSMA)
|
1
|
PSMA DCFBC
|
(18F)
|
(N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-F-fluorobenzyl-L-cysteine) (F-DCFBC)
|
4
|
PSMA Df-IAB2M
|
(89Zr)
|
Zr-89-desferrioxamine-IAB2M
|
1
|
RM2
|
(68Ga)
|
68Ga-RM2 stands for Galium-68 labeled DOTA-4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2
|
3
|
Sodium Fluoride
|
(18F)
|
Sodium Fluoride
|
1
|
uPAR NOTA
|
(68Ga)
|
Urokinase Plasminogen Activator Receptor
|
1
|